In this third episode of the "Dialogues in CDx" podcast series, you’ll listen to the distinguished guests Dr. Phillippe Taniere and Dr. Shobhit Baijal once more. The previous episode dissected the PD-L1 testing journey from biopsy to report. This episode will focus on the topic of PD-L1 reporting: What information should the pathologist provide for the oncologist? What information helps the oncologist make the best treatment decisions?

As in the second episode, perspectives from both a pathologist and an oncologist are presented. Dr. Phillipe Taniere is a Consultant Histopathologist and Clinical Service Lead for Molecular Pathology at University Hospitals Birmingham in UK. Dr. Taniere’s department completed 20,000 CDx tests last year.

Also joining the discussion is Dr. Shobhit Baijal, a Consultant Medical Oncologist at the University Hospitals Birmingham NHS Trust and an Honorary Associate Professor at the University of Birmingham, where he specializes in the treatment of thoracic and colorectal malignancies. Dr. Baijal specializes in all forms of cancer therapy and is a UK Chief and Principal Investigator for National and International studies. He is also a steering committee member of the British Thoracic Oncology Group. His vast experience provides invaluable input to the discussion.

This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠CDx Digital Education Portal⁠ today.

D0130749_1.00

The second episode of the "Dialogues in CDx" podcast series takes a closer look at the PD-L1 testing journey. Using England as example, you’ll learn about the process from start to finish, and topics, such as the importance of turnaround times, reflex testing, optimal oncologist-pathologist collaboration, and more, are discussed.  

Joining this discussion are two esteemed guests, providing perspectives from both a pathologist’s and an oncologist’s viewpoint. Dr. Phillipe Taniere is a Consultant Histopathologist and Clinical Service Lead for Molecular Pathology at University Hospitals Birmingham. Dr. Taniere’s department completed 20,000 CDx tests last year and is therefore an ideal candidate for this discussion.  

Also joining is Dr. Shobhit Baijal, a Consultant Medical Oncologist at the University Hospitals Birmingham NHS Trust and an Honorary Associate Professor at the University of Birmingham where he specializes in the treatment of thoracic and colorectal malignancies. Dr. Baijal specializes in all forms of cancer therapy and is a UK Chief and Principal Investigator for National and International studies. He is also a steering committee member of the British Thoracic Oncology Group. His vast experience provides invaluable input to the discussion. 

This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal today.

D0130686_1.00

In this inaugural episode of the "Dialogues in CDx" podcast series, you’ll hear about the intricate relationship between diagnostic cutoffs and clinical data. In the PD-L1 space, there are multiple scoring algorithms, cutoffs, assays, and staining platforms for various indications, leading to frustration among pathologists. This episode centers on the question "Why is the PD-L1 domain so complex?” To answer this, the origins of cutoffs and algorithms, and how they are applied to the right patients, are explored.   

To discuss the topic, the host Scott W. Boyer is joined by two esteemed guests, one representing the perspective of the pathologist working in clinical practice, and the other representing the perspective of the industry that develops CDx assays.  Dr. Hans-Ulrich Schildhaus is Executive Vice President of Pathology and Medical Affairs at Discovery Life Sciences Biomarker Services, as well as Medical Director and one of the Managing Directors of Pathology Nordhessen. Dr. Douglas Clark is the Chief Pathologist in the CDx Division at Agilent Technologies. He has expertise in pathology artificial intelligence, cytopathology, and molecular diagnostics.  

This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠CDx Digital Education Portal⁠ today.⁠

D0130685_1.00

In this new podcast series, Agilent brings together leading pathologists, oncologists, and CDx specialists to explore key challenges and solutions in the field of companion diagnostics. Through peer-to-peer discussions, these experts share fresh insights, real-world approaches, and the latest developments shaping the field. Stay tuned for episode 1 that will be launched on May 20.

This podcast series is for pathologists, oncologists, and others with a professional interest in the pivotal issues shaping the field of companion diagnostics. 

The podcast is hosted by Scott W. Boyer, PhD, MBA. Scott is a global product manager at Agilent Technologies, overseeing CDx products and advocating for customer needs. With expertise in the development of both IHC- and PCR-based diagnostics, Scott has published over a dozenpeer-reviewed papers in hematology and immunology. Join Scott and renowned guests for insightful discussions on product innovation and diagnostics.  

This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent’s ⁠CDx Digital Education Portal⁠ .⁠

D0130747_1.00